IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
Street Ad dress: Carl Zeiss-Ring 3, D-85737
Ismaning
Tel: +49 89 244040
Fax: +49 89 24404100
Email: info@sandoz.de
Home Page: www.sandoz.de
De scrip tion: Sales/detailer. Prod uct ranges in -
clude: phar ma ceu ti cal prod ucts (branded,
unbranded, pre scrip tion, non-pre scrip tion), bi o -
log i cal prod ucts. Es tab lished 2004. 230 phar ma -
ceu ti cal employees in 2007.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 165 (2007)
Con tacts (Pharm): Chair man: Hakka Taissel;
Com mer cial Op er a tions: Stefan Uab, Dominik
Vauhage; Mar ket Re search: Marco Wolf
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 220-230 mil lion
Prod ucts (% of Sales by Lead ing 5): 25-30%
Ther a peu tic Classes (% of Sales by Lead ing
5): 45-50%
Dose Forms (% of Sales by Lead ing 5):
90-95%
Prin ci pal Prod ucts:
OMEPRAZOL SANDOZ (antiulcerant)
FENTAN.SAND. BET.M (an al ge sic nar cotic)
SIMVASTATIN SANDOZ (cho les terol/triglyceride
reg u lat ing prep a ra tion)
CAL CIUM D SANDOZ (cal cium prod uct)
METO-SUCCINAT SDZ (beta-blocker agent plain)
Ther a peu tic Range:
min eral sup ple ments 12%
an al ge sics 12%
ant ac ids/antiflatulents/antiulcerants 10%
beta-block ing agents 10%
lipid-reg u lat ing/antiatheroma prep a ra tions 7%
Lead ing Dose Forms:
tab lets 44%
coated tab lets 23%
cap sules 15%
med i cal dress ings 6%
pre-filled sy ringes/pens 4%
GREECE
NOVARTIS
Full Name: Novartis (Hel las) SACI
Postal Ad dress: PO Box 52001, Meta mor pho sis,
GR-144 10 Ath ens
Street Ad dress: Na tional Road No 1 (12th km),
Meta mor pho sis, GR-144 51 Ath ens
Tel: +30 21 0281 1712
Fax: +30 21 0281 2014
Home Page: www.novartis.gr
De scrip tion: Man u fac turer, packager/as sem -
bler, im porter, dis trib u tor, pro moter,
sales/detailer. Prod uct ranges in clude: phar ma -
ceu ti cal prod ucts (branded, pre scrip tion,
non-pre scrip tion), hos pi tal pharmaceuticals, di -
etetic/nu tri tional prod ucts, oph thal mic prod ucts.
Es tab lished 1997. 430 phar ma ceu ti cal em ploy ees
in 2005. Di vi sions in clude: Novartis Con sumer
Health. Pharmaceuticals; Consumer Health;
Health Nutrition.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 222 (2005)
Con tacts (Pharm): Chair man: A. Wyss; Com -
mer cial Op er a tions: S. Varthalis; Man u fac ture: E.
Theodoridou; Mar ket Re search: A. Papachatzis;
Re search & De vel op ment: P. Pontikis; Gen eral
Con tact: P. Giachni
Par ent of: Famar, Greece (3%).
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 410-420 mil lion
Prod ucts (% of Sales by Lead ing 5): 45-50%
Ther a peu tic Classes (% of Sales by Lead ing
5): 60-65%
Dose Forms (% of Sales by Lead ing 5):
90-95%
Prin ci pal Prod ucts:
EXELON (anti-Alz hei mer prod uct)
CO DIOVAN (an gio ten sin-II an tag o nist com bi na -
tion)
DIOVAN (an gio ten sin-II an tag o nist plain)
GLIVEC (antineoplastic other)
EXJADE (iron-che lat ing agent)
Ther a peu tic Range:
renin-an gio ten sin sys tem agents 28%
CNS drugs other 17%
antineoplastics 7%
antiasthma and COPD prod ucts 5%
immunosuppressive agents 5%
Lead ing Dose Forms:
coated tab lets 43%
cap sules 24%
liq uids 11%
tab lets 9%
med i cal dress ings 4%
NOVARTIS OPHTHALMICS
Street Ad dress: 30 Vasileos Georgiou and
Mikras Asias, GR-152 33 Halandri
Tel: +30 210 689 23 19
Fax: +30 210 689 26 55
© 2009 IMS Health In cor po rated or its af fil i ates Page 173